Jayempi Európska únia - slovinčina - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - zavrnitev presadka - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Bekemv Európska únia - slovinčina - EMA (European Medicines Agency)

bekemv

amgen technology (ireland) uc - eculizumab - hemoglobinurija, paroksizmal - imunosupresivi - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). dokazila o kliničnih koristi je dokazana pri bolnikih z haemolysis z klinični simptom(i) okvirni visoke aktivnosti bolezni, ne glede na to, transfuzijo zgodovine (glej poglavje 5.

Integrilin Európska únia - slovinčina - EMA (European Medicines Agency)

integrilin

glaxosmithkline (ireland) limited - eptifibatid - angina, unstable; myocardial infarction - antitrombotična sredstva - integrilin je namenjen uporabi z acetilsalicilno kislino in nefrakcioniranim heparinom. integrilin je indicirano za preprečevanje zgodnje miokardni infarkt pri bolnikih, ki predstavljajo z nestabilno angino pektoris ali ne-q-val, miokardni infarkt z zadnjo epizodo bolečine v prsih, ki se pojavljajo v 24 urah in z ekg spremembe in / ali zvišan srčni encimi. bolniki najbolj verjetno, da koristi od integrilin zdravljenje, so tiste z visokim tveganjem za razvoj miokardnega infarkta v prvih 3-4 dni po nastopu akutne angina simptomov, vključno z, na primer tiste, ki jih je verjetno, da opravijo zgodnji perkutani transluminal koronarno angioplastiko (ptca).

Parareg Európska únia - slovinčina - EMA (European Medicines Agency)

parareg

dompé biotec s.p.a. - cinakalcet - hypercalcemia; parathyroid neoplasms; hyperparathyroidism - kalcij homeostaza - zdravljenje sekundarnega hiperparatiroidizma (hpt) pri bolnikih s končno ledvično boleznijo (esrd) pri vzdrževalnem dializnem zdravljenju. mimpara se lahko uporablja kot del terapevtski režim, vključno z fosfat veziv in/ali vitamina d sterolov, kot je primerno (glej poglavje 5. zmanjšanje hypercalcaemia pri bolnikih z:-parathyroid karcinom. - primarni hpt, za katere parathyroidectomy bi se kazalo na osnovi seruma calciumlevels (kot je opredeljeno z ustreznimi smernicami za zdravljenje), ampak v katero parathyroidectomy ni klinično primerno ali je kontraindicirana.